Law360 (August 27, 2019, 6:05 PM EDT) -- Prothena investors have negotiated a $15.75 million settlement with the neuroscience research and development company, which would end claims that it hid salient details of a clinical trial for a new drug and hurt shareholders when revelations about the trial made its stock price fall by nearly 70%.
The investors — led by Granite Point Capital and investor Simon James, who claim that their combined losses from the stock drop total $2 million — asked Judge Andrew L. Carter Jr. of New York's Southern District for preliminary approval of the settlement on Monday.
The proposal comes nearly six months after the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!